ArticleBioImpacts : BI2025
Uncovering the anticancer effects of Bhallataka Taila in lung cancer: A metabolomic and network pharmacology approach.
Article in BioImpacts : BI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Integrative Omics and Network Pharmacology Approach to Evaluate the Antiulcer Activity ofACS omega · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bhallataka ( Methods: Untargeted metabolomics using liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed to evaluate the metabolites in Bhallataka taila, identify key protein targets and link them to cellular pathways through bioinformatics-based network pharmacology. Protein targets were mapped using BindingDB, and pathway enrichment was analyzed using STRINGdb. An Results: Metabolomics combined with network pharmacology detected 2023 unique metabolites at the MS1 level and 216 metabolites at the MS2 level. Bhallataka taila metabolites were found to interact with 180 human target proteins identified through BindingDB analysis. These target proteins were mapped to key cancer regulatory signaling pathways, along with TNF-related apoptosis-inducing ligand (TRAIL), protease-activated receptor-1 (PAR1)-mediated thrombin signaling, Syndecan-1 and Glypican pathways, and vascular endothelial growth factor receptor (VEGFR)1/2 pathways. Conclusion: This data-driven study can help researchers identify promising cancer treatment candidates and validate their efficacy. This approach integrates traditional knowledge with modern scientific techniques to reinforce the anticancer potential of Bhallataka taila and its mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.